Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 889

1.

Causal Pathways from Blood Pressure to Larger Qrs Amplitudes a Mendelian Randomization Study.

Van Der Ende MY, Hendriks T, Van Veldhuisen DJ, Snieder H, Verweij N, Van Der Harst P.

Sci Rep. 2018 Apr 11;8(1):5817. doi: 10.1038/s41598-018-24002-0.

2.

Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging.

Te Rijdt WP, Ten Sande JN, Gorter TM, van der Zwaag PA, van Rijsingen IA, Boekholdt SM, van Tintelen JP, van Haelst PL, Planken RN, de Boer RA, Suurmeijer AJH, van Veldhuisen DJ, Wilde AAM, Willems TP, van Dessel PFHM, van den Berg MP.

Eur Heart J Cardiovasc Imaging. 2018 Apr 6. doi: 10.1093/ehjci/jey047. [Epub ahead of print]

PMID:
29635323
3.

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.

Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV.

Eur J Heart Fail. 2018 Mar 8. doi: 10.1002/ejhf.1170. [Epub ahead of print] Review.

PMID:
29520964
4.

Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P.

Eur J Heart Fail. 2018 Feb 27. doi: 10.1002/ejhf.1154. [Epub ahead of print]

PMID:
29484788
5.

The Failing Heart Stimulates Tumor Growth by Circulating Factors.

Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, van Veldhuisen DJ, Westenbrink BD, van der Meer P, Silljé HHW, de Boer RA.

Circulation. 2018 Feb 19. pii: CIRCULATIONAHA.117.030816. doi: 10.1161/CIRCULATIONAHA.117.030816. [Epub ahead of print]

PMID:
29459363
6.

Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.

Rienstra M, Hobbelt AH, Alings M, Tijssen JGP, Smit MD, Brügemann J, Geelhoed B, Tieleman RG, Hillege HL, Tukkie R, Van Veldhuisen DJ, Crijns HJGM, Van Gelder IC; RACE 3 Investigators.

Eur Heart J. 2018 Feb 1. doi: 10.1093/eurheartj/ehx739. [Epub ahead of print]

PMID:
29401239
7.

Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.

Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Ter Maaten JM, Lang CC, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Voors AA.

J Am Coll Cardiol. 2018 Jan 30;71(4):386-398. doi: 10.1016/j.jacc.2017.11.041.

PMID:
29389354
8.

Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients.

Grote Beverborg N, Klip IT, Meijers WC, Voors AA, Vegter EL, van der Wal HH, Swinkels DW, van Pelt J, Mulder AB, Bulstra SK, Vellenga E, Mariani MA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Circ Heart Fail. 2018 Feb;11(2):e004519. doi: 10.1161/CIRCHEARTFAILURE.117.004519.

PMID:
29382661
9.

N-terminal pro-B-type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure.

Tromp J, Richards AM, Tay WT, Teng TK, Yeo PSD, Sim D, Jaufeerally F, Leong G, Ong HY, Ling LH, van Veldhuisen DJ, Jaarsma T, Voors AA, van der Meer P, de Boer RA, Lam CSP.

ESC Heart Fail. 2018 Apr;5(2):279-287. doi: 10.1002/ehf2.12252. Epub 2018 Jan 30.

10.

Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations.

van der Meer P, Grote Beverborg N, Pfeffer MA, Olson K, Anand IS, Westenbrink BD, McMurray JJV, Swedberg K, Young JB, Solomon SD, van Veldhuisen DJ.

Circ Heart Fail. 2018 Feb;11(2):e004431. doi: 10.1161/CIRCHEARTFAILURE.117.004431.

PMID:
29367268
11.

Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.

Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P.

Eur J Heart Fail. 2018 Jan 12. doi: 10.1002/ejhf.1079. [Epub ahead of print]

PMID:
29327797
12.

Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Gorter TM, Streng KW, van Melle JP, Rienstra M, Dickinson MG, Lam CSP, Hummel YM, Voors AA, Hoendermis ES, van Veldhuisen DJ.

Am J Cardiol. 2018 Mar 1;121(5):621-627. doi: 10.1016/j.amjcard.2017.11.040. Epub 2017 Dec 11.

PMID:
29307460
13.

Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.

Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, de Borst MH.

Int J Cardiol. 2018 Feb 15;253:84-90. doi: 10.1016/j.ijcard.2017.10.010.

PMID:
29306478
14.

Proteomic diversity of high-density lipoprotein explains its association with clinical outcome in patients with heart failure.

Emmens JE, Jones DJL, Cao TH, Chan DCS, Romaine SPR, Quinn PA, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Metra M, de Boer RA, Voors AA, Ng LL.

Eur J Heart Fail. 2018 Feb;20(2):260-267. doi: 10.1002/ejhf.1101. Epub 2017 Dec 18.

PMID:
29251807
15.

Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation.

Gorter TM, van Melle JP, Rienstra M, Borlaug BA, Hummel YM, van Gelder IC, Hoendermis ES, Voors AA, van Veldhuisen DJ, Lam CSP.

J Card Fail. 2018 Mar;24(3):177-185. doi: 10.1016/j.cardfail.2017.11.005. Epub 2017 Nov 29.

16.

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide.

Klaassen SHC, Tromp J, Nienhuis HLA, van der Meer P, van den Berg MP, Blokzijl H, van Veldhuisen DJ, Hazenberg BPC.

Am J Cardiol. 2018 Jan 1;121(1):107-112. doi: 10.1016/j.amjcard.2017.09.029. Epub 2017 Oct 14.

17.

Anemia in Heart Failure: Still Relevant?

Grote Beverborg N, van Veldhuisen DJ, van der Meer P.

JACC Heart Fail. 2018 Mar;6(3):201-208. doi: 10.1016/j.jchf.2017.08.023. Epub 2017 Nov 8. Review.

PMID:
29128254
18.

Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH.

van der Pol A, Gil A, Silljé HHW, Tromp J, Ovchinnikova ES, Vreeswijk-Baudoin I, Hoes M, Domian IJ, van de Sluis B, van Deursen JM, Voors AA, van Veldhuisen DJ, van Gilst WH, Berezikov E, van der Harst P, de Boer RA, Bischoff R, van der Meer P.

Sci Transl Med. 2017 Nov 8;9(415). pii: eaam8574. doi: 10.1126/scitranslmed.aam8574.

PMID:
29118264
19.

The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis.

Bayes-Genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Metra M, Lupón J, Voors AA.

J Am Coll Cardiol. 2017 Oct 24;70(17):2128-2136. doi: 10.1016/j.jacc.2017.08.057.

20.

Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology.

Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschöpe C, de Boer RA.

Eur J Heart Fail. 2018 Jan;20(1):16-37. doi: 10.1002/ejhf.1029. Epub 2017 Oct 16. Review.

PMID:
29044932
21.

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.

Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, Manzano L, McMurray JJV, Ruschitzka F, van Veldhuisen DJ, von Lueder TG, Böhm M, Andersson B, Kjekshus J, Packer M, Rigby AS, Rosano G, Wedel H, Hjalmarson Å, Wikstrand J, Kotecha D; Beta-blockers in Heart Failure Collaborative Group.

Eur Heart J. 2018 Jan 1;39(1):26-35. doi: 10.1093/eurheartj/ehx564.

22.

Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction.

Kaye DM, Silvestry FE, Gustafsson F, Cleland JG, van Veldhuisen DJ, Ponikowski P, Komtebedde J, Nanayakkara S, Burkhoff D, Shah SJ.

Eur J Heart Fail. 2017 Dec;19(12):1690-1697. doi: 10.1002/ejhf.930. Epub 2017 Oct 11.

23.

Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements.

Hummel YM, Liu LCY, Lam CSP, Fonseca-Munoz DF, Damman K, Rienstra M, van der Meer P, Rosenkranz S, van Veldhuisen DJ, Voors AA, Hoendermis ES.

Eur J Heart Fail. 2017 Dec;19(12):1651-1660. doi: 10.1002/ejhf.957. Epub 2017 Oct 6.

PMID:
28984057
24.

Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome.

Siegmund AS, Kampman MAM, Bilardo CM, Balci A, van Dijk APJ, Oudijk MA, Mulder BJM, Roos-Hesselink JW, Sieswerda GT, Koenen SV, Sollie-Szarynska KM, Ebels T, van Veldhuisen DJ, Pieper PG; ZAHARA investigators.

Int J Cardiol. 2017 Dec 15;249:145-150. doi: 10.1016/j.ijcard.2017.09.167. Epub 2017 Sep 22.

PMID:
28966042
25.

Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF study.

Welsh P, Kou L, Yu C, Anand I, van Veldhuisen DJ, Maggioni AP, Desai AS, Solomon SD, Pfeffer MA, Cheng S, Gullestad L, Aukrust P, Ueland T, Swedberg K, Young JB, Kattan MW, Sattar N, McMurray JJV.

Eur J Heart Fail. 2018 Feb;20(2):268-277. doi: 10.1002/ejhf.988. Epub 2017 Sep 27.

PMID:
28960777
26.

Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?

Cotter G, Metra M, Davison BA, Jondeau G, Cleland JGF, Bourge RC, Milo O, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Kobrin I, Rainisio M, Senger S, Edwards C, McMurray JJV, Teerlink JR; VERITAS Investigators.

Eur J Heart Fail. 2018 Feb;20(2):317-322. doi: 10.1002/ejhf.889. Epub 2017 Sep 4.

27.

High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction.

Groot HE, Karper JC, Lipsic E, van Veldhuisen DJ, van der Horst ICC, van der Harst P.

Int J Cardiol. 2017 Dec 1;248:51-56. doi: 10.1016/j.ijcard.2017.08.027. Epub 2017 Aug 10.

28.

Vitamin D supplementation in heart failure: case closed?

de Boer RA, Meems LMG, van Veldhuisen DJ.

Eur Heart J. 2017 Aug 1;38(29):2287-2289. doi: 10.1093/eurheartj/ehx341. No abstract available.

PMID:
28810714
29.

Coronary angiography in worsening heart failure: determinants, findings and prognostic implications.

Ferreira JP, Rossignol P, Demissei B, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F.

Heart. 2018 Apr;104(7):606-613. doi: 10.1136/heartjnl-2017-311750. Epub 2017 Aug 10.

30.

Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.

Hartman MHT, Prins JKB, Schurer RAJ, Lipsic E, Lexis CPH, van der Horst-Schrivers ANA, van Veldhuisen DJ, van der Horst ICC, van der Harst P.

Clin Res Cardiol. 2017 Dec;106(12):939-946. doi: 10.1007/s00392-017-1140-z. Epub 2017 Jul 28.

31.

Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension.

Klaassen SHC, Liu LCY, Hummel YM, Damman K, van der Meer P, Voors AA, Hoendermis ES, van Veldhuisen DJ.

J Card Fail. 2017 Nov;23(11):777-782. doi: 10.1016/j.cardfail.2017.07.397. Epub 2017 Jul 20.

32.

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A; EFFECT-HF Investigators.

Circulation. 2017 Oct 10;136(15):1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027497. Epub 2017 Jul 12.

33.

Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure.

Damman K, Valente MAE, van Veldhuisen DJ, Cleland JGF, O'Connor CM, Metra M, Ponikowski P, Cotter G, Davison B, Givertz MM, Bloomfield DM, Hillege HL, Voors AA.

Int J Mol Sci. 2017 Jul 8;18(7). pii: E1470. doi: 10.3390/ijms18071470.

34.

Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV.

JACC Heart Fail. 2017 Jul;5(7):471-482. doi: 10.1016/j.jchf.2017.04.013. Epub 2017 Jun 26. Review.

PMID:
28662936
35.

Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial : Differential Response in Acute Heart Failure.

Liu LCY, Valente MAE, Postmus D, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, van Veldhuisen DJ, Hillege HL, van der Meer P, Voors AA.

Cardiovasc Drugs Ther. 2017 Jun;31(3):281-293. doi: 10.1007/s10557-017-6726-1.

36.

A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure.

Sharma A, Demissei BG, Tromp J, Hillege HL, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Davison BA, Givertz MM, Bloomfield DM, Dittrich H, van Veldhuisen DJ, Cotter G, Ezekowitz JA, Khan MAF, Voors AA.

Eur J Heart Fail. 2017 Oct;19(10):1310-1320. doi: 10.1002/ejhf.912. Epub 2017 Jun 21.

37.

Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction.

Tromp J, Khan MAF, Mentz RJ, O'Connor CM, Metra M, Dittrich HC, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, Van Veldhuisen DJ, Hillege HL, Voors AA, van der Meer P.

JACC Heart Fail. 2017 Jul;5(7):507-517. doi: 10.1016/j.jchf.2017.04.007. Epub 2017 Jun 14.

38.

Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF.

Ferreira JP, Rossignol P, Machu JL, Sharma A, Girerd N, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Lang CC, Ter Maaten JM, Metra M, Ng L, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Voors A, Zannad F.

Eur J Heart Fail. 2017 Oct;19(10):1284-1293. doi: 10.1002/ejhf.900. Epub 2017 Jun 5.

PMID:
28580625
39.

Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation.

Mulder BA, Van Veldhuisen DJ, Rienstra M.

JACC Heart Fail. 2017 Jun;5(6):466-467. doi: 10.1016/j.jchf.2017.03.010. No abstract available.

PMID:
28571601
40.

Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension.

Gorter TM, van Veldhuisen DJ, Voors AA, Hummel YM, Lam CSP, Berger RMF, van Melle JP, Hoendermis ES.

Eur Heart J Cardiovasc Imaging. 2018 Apr 1;19(4):425-432. doi: 10.1093/ehjci/jex133.

PMID:
28531295
41.

Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Mulder BA, Damman K, Van Veldhuisen DJ, Van Gelder IC, Rienstra M.

Clin Cardiol. 2017 Sep;40(9):740-745. doi: 10.1002/clc.22725. Epub 2017 May 17.

42.

Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure.

Moliner P, Jankowska EA, van Veldhuisen DJ, Farre N, Rozentryt P, Enjuanes C, Polonski L, Meroño O, Voors AA, Ponikowski P, Van der Meer P, Comin-Colet J.

Int J Cardiol. 2017 Sep 15;243:360-366. doi: 10.1016/j.ijcard.2017.04.110. Epub 2017 May 3.

PMID:
28511855
43.

Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Böhm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson Å, Kjekshus J, Cleland JGF; Beta-Blockers in Heart Failure Collaborative Group.

J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896. doi: 10.1016/j.jacc.2017.04.001. Epub 2017 Apr 30. Review.

44.

Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).

Klaassen SHC, Lemmink HH, Bijzet J, Glaudemans AWJM, Bos R, Plattel W, van den Berg MP, Slart RHJA, Nienhuis HLA, van Veldhuisen DJ, Hazenberg BPC.

Cardiovasc Pathol. 2017 Jul - Aug;29:19-22. doi: 10.1016/j.carpath.2017.04.002. Epub 2017 Apr 18.

45.

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P.

Eur J Heart Fail. 2018 Jan;20(1):125-133. doi: 10.1002/ejhf.823. Epub 2017 Apr 24.

46.

Measuring Pulmonary Artery Pressures in Heart Failure: A New Useful Diagnostic Tool?

Gorter TM, Rienstra M, van Veldhuisen DJ.

Circulation. 2017 Apr 18;135(16):1518-1521. doi: 10.1161/CIRCULATIONAHA.117.027668. No abstract available.

47.

Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure.

Packer M, O'Connor C, McMurray JJV, Wittes J, Abraham WT, Anker SD, Dickstein K, Filippatos G, Holcomb R, Krum H, Maggioni AP, Mebazaa A, Peacock WF, Petrie MC, Ponikowski P, Ruschitzka F, van Veldhuisen DJ, Kowarski LS, Schactman M, Holzmeister J; TRUE-AHF Investigators.

N Engl J Med. 2017 May 18;376(20):1956-1964. doi: 10.1056/NEJMoa1601895. Epub 2017 Apr 12.

48.

Predictors of left ventricular remodeling after ST-elevation myocardial infarction.

Hendriks T, Hartman MHT, Vlaar PJJ, Prakken NHJ, van der Ende YMY, Lexis CPH, van Veldhuisen DJ, van der Horst ICC, Lipsic E, Nijveldt R, van der Harst P.

Int J Cardiovasc Imaging. 2017 Sep;33(9):1415-1423. doi: 10.1007/s10554-017-1131-1. Epub 2017 Apr 7.

49.

Iron deficiency and red cell indices in patients with heart failure.

Tkaczyszyn M, Comín-Colet J, Voors AA, van Veldhuisen DJ, Enjuanes C, Moliner-Borja P, Rozentryt P, Poloński L, Banasiak W, Ponikowski P, van der Meer P, Jankowska EA.

Eur J Heart Fail. 2018 Jan;20(1):114-122. doi: 10.1002/ejhf.820. Epub 2017 Apr 6.

PMID:
28386910
50.

New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations.

Screever EM, Meijers WC, van Veldhuisen DJ, de Boer RA.

Expert Opin Pharmacother. 2017 May;18(7):645-655. doi: 10.1080/14656566.2017.1316377. Epub 2017 Apr 17. Review.

PMID:
28375036

Supplemental Content

Loading ...
Support Center